Objective To screen moyamoya disease-related serum proteins and to explore associations of the protein with the disease for providing evidences to the development of molecular targeted therapy.
Methods Serum samples were collected from 11 moyamoya disease patients and 20 healthy controls. The samples were labeled with isobaric tags for relative or absolute quantitation (iTRAQ) after the elimination of abundant proteins such as immunoglobulin G (IgG) and albumin and trypsin digestion; then differential proteins in the samples were detected with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The identified transforming growth factor β1 (TGF-β1) was verified with enzyme-linked immunosorbent assay (ELISA).
Results Among the 202 moyamoya disease-related serum proteins identified, 13 were up-regulated and 7 were down-regulated. Significantly increased vitamin D-binding protein (D6RF35) (1.22 ± 0.48 ng/ml) and decreased coenzyme Q10B (CoQ10B) (0.81 ± 0.25 ng/ml) were detected in the serum samples of moyamoya disease patients (both P < 0.05). The receiver operating characteristic (ROC) curve analysis demonstrated a larger area under the ROC curve (AUC) (71.4%) of the CoQ10B than that of D6RF35 (61.7%).
Conclusion CoQ10 may be a potential serum protein marker better than D6RF35 for moyamoya disease and may play an important role in the incidence of moyamoya disease.
DownLoad: